Center for International Blood & Marrow Transplant Research (CIBMTR)

Abstract submission for is now open! Make sure to submit your latest HCT, cell, and/or gene therapy research by 11:59 p.m. PT on Oct. 9! Read more about abstract submission here: https://tandemmeetings.com/Abstracts/Submit-Abstract

JOB POSTING: CIBMTR is seeking a part time (0.1 FTE) Scientific Director to lead our Infection and Immune Reconstitution Working Committee. Learn more about this important position, here:

cibmtr.org

The largest ever long-term study of people who donated peripheral blood stem cells ( ) show that medicines for these donations are safe. Learn more about this recent CIBMTR study:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/Donor-Health-and-Safety/2024.04.30-Stefanski.pdf

CIBMTR's August Newsletter is now available! Read about two of our working committees, the new OPTIMIZE study, the HLA_SAVE cumulative data extract, caregiver requirements for alloHCT, and much more. Read more online: https://cibmtr.org/CIBMTR/About/News/Newsletters/August-2024-Newsletter/

New CIBMTR research just published in American Society of Clinical Oncology Journal of Clinical Oncology: Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors. Read more:

Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors | Journal of Clinical Oncology PURPOSE Access to allogeneic hematopoietic cell transplantation (HCT) remains limited among persons of non-European ancestry if human leukocyte antigen (HLA) matching is required. We evaluated whether post-transplant cyclophosphamide (PTCy)–based graft-versus-host disease (GVHD) prophylaxis improv...

can be a dangerous infection, particularly in people who recently got or -T therapy. Revaccination after BMT is important to boost immunity. Learn more about this BMT CTN study:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/Trends-in-Transplant/2024.05.27-Hill.pdf

People’s social functioning dropped for a few months after certain blood cancer treatments. But a year later, their social functioning returned to where they were prior to treatment, a recent CIBMTR study found:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/Social-and-Financial-Aspects-of-Transplant/2023.02.16-Cusatis.pdf

Less than 1 in 5 children with sickle cell disease have a tissue-type matched, sibling donor who doesn’t have the disease. A small clinical trial during 2008-2014 showed that transplant from unrelated donors is an option. Learn more about this BMT CTN study:https://cibmtr.org/Files/Patient-Summaries/Diseases-and-Conditions/Other-Diseases/2024.02.11-Eapen.pdf

Doctors recommend that children to return to school at different times after , which means that guidelines are needed. Learn more about this CIBMTR study:https://cibmtr.org/Files/Patient-Summaries/Diseases-and-Conditions/Cancer-in-Children-and-Teens/2024.02.21-Bhatt.pdf

A new BMT CTN study shows that giving gilteritinib after BMT helps people who have FLT3 AML and have MRD. Read more about this study:https://cibmtr.org/Files/Patient-Summaries/Diseases-and-Conditions/Acute-Leukemia/2024.03.12-Levis.pdf

CIBMTR's May Newsletter is now available. Read an update from our Advisory Committee Chair, updates from the and Cell Disorders Working Committees, and reflect back on February's meetings! Available online: https://cibmtr.org/CIBMTR/About/News/Newsletters/May-2024-Newsletter

A ​person’s ​race ​and ​health​ insurance ​may​ affect​ which ​treatments ​they​ receive​ for multiple myeloma. Learn more about this recent CIBMTR study:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/Access-to-Transplant/2024.01.10-Esteghamat.pdf

Though can cure many diseases, it also can have serious long-term side effects such as , lung conditions, hormone changes or cognitive difficulties. Special checkups are important. Read about more recommendations, here:https://cibmtr.org/Files/Patient-Summaries/Other-Topics-Related-to-Transplant/Late-Effects-and-Quality-of-Life/2024.02.23-Rotz.pdf

CIBMTR's 2023 Annual Report is now available to view on our website. Thank you for helping us make 2023 another successful year!
https://cibmtr.org/Files/Administrative-Reports/Annual-Reports/2023-Annual-Report.pdf

Thank you to everyone who attended . Safe travels and we look forward to seeing you next year in Honolulu, HI, for American Society for Transplantation and Cellular Therapy

The final plenary session kicks off at 4:15 p.m.: “Selecting an Ideal HLA-Mismatched Donor: Old Art, New Science.” American Society for Transplantation and Cellular Therapy

Make sure to attend “CIBMTR Collaborate: The Insider Scoop” from 1-3 p.m. this afternoon!

Saturday’s American Society for Transplantation and Cellular Therapy plenary session starts at 8:30 a.m.: “The Future of Cellular and Gene Therapy.” Arrive early for the day’s welcome and awards session!

John F. DiPersio, MD, PhD, will present the E. Donnall Thomas Lecture at 5:50 p.m. American Society for Transplantation and Cellular Therapy

CIBMTR congratulates Robert J. Soiffer, MD, on presenting tonight’s honorable Mortimer M. Bortin Lecture at , “In Search of the Holy Grail: Uncoupling GVL and GVH - Déjà Vu All Over Again?”

Congratulations to Professor Xiao-Jun Huang, MD, on receiving the 2024 CIBMTR Distinguished Service Award at !

Robert J. Soiffer, MD, will present the Mortimer M. Bortin Lecture at 5:10 p.m. American Society for Transplantation and Cellular Therapy

Join us in congratulating our CIBMTR Distinguished Service Award recipient and the ASTCT Lifetime Achievement Award recipient this evening! American Society for Transplantation and Cellular Therapy

Friday afternoon’s CIBMTR Working Committee meetings will get underway in 15 minutes.

Good morning! Begin your day with our daily welcome and awards at 8:15 a.m., followed by the Best Abstracts session, starting at 8:30 a.m. in Stars at Night B2 & B3. American Society for Transplantation and Cellular Therapy

This afternoon’s plenary session, “Mucosal Immunology and Host/Pathogen Interactions Impacting Tissue Damage,” begins in 15 minutes! American Society for Transplantation and Cellular Therapy

Four more CIBMTR Working Committees are meeting at 1 p.m. today.

Today’s first plenary session begins at 8:30 a.m.: “Novel Antigen Discovery for Transplant and Cellular Therapies.” Arrive by 8:15 a.m. for the day’s welcome and awards! American Society for Transplantation and Cellular Therapy

Our second plenary session of begins at 5 p.m.: “Biology of Relapse After Transplant and Cellular Therapy.” American Society for Transplantation and Cellular Therapy

CIBMTR Working Committee meetings begin this afternoon! Look at this image for a snapshot of today’s meetings.